المؤلفون: Andrea Weber, Vincent T. van Hees, Michael J. Stein, Sylvia Gastell, Karen Steindorf, Florian Herbolsheimer, Stefan Ostrzinski, Tobias Pischon, Mirko Brandes, Lilian Krist, Michael Marschollek, Karin Halina Greiser, Katharina Nimptsch, Berit Brandes, Carmen Jochem, Anja M. Sedlmeier, Klaus Berger, Hermann Brenner, Christoph Buck, Stefanie Castell, Marcus Dörr, Carina Emmel, Beate Fischer, Claudia Flexeder, Volker Harth, Antje Hebestreit, Jana-Kristin Heise, Bernd Holleczek, Thomas Keil, Lena Koch-Gallenkamp, Wolfgang Lieb, Claudia Meinke-Franze, Karin B. Michels, Rafael Mikolajczyk, Alexander Kluttig, Nadia Obi, Annette Peters, Börge Schmidt, Sabine Schipf, Matthias B. Schulze, Henning Teismann, Sabina Waniek, Stefan N. Willich, Michael F. Leitzmann, Hansjörg Baurecht

المصدر: Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)

مصطلحات موضوعية: Medicine, Science

الوصف: Abstract Large population-based cohort studies utilizing device-based measures of physical activity are crucial to close important research gaps regarding the potential protective effects of physical activity on chronic diseases. The present study details the quality control processes and the derivation of physical activity metrics from 100 Hz accelerometer data collected in the German National Cohort (NAKO). During the 2014 to 2019 baseline assessment, a subsample of NAKO participants wore a triaxial ActiGraph accelerometer on their right hip for seven consecutive days. Auto-calibration, signal feature calculations including Euclidean Norm Minus One (ENMO) and Mean Amplitude Deviation (MAD), identification of non-wear time, and imputation, were conducted using the R package GGIR version 2.10-3. A total of 73,334 participants contributed data for accelerometry analysis, of whom 63,236 provided valid data. The average ENMO was 11.7 ± 3.7 mg (milli gravitational acceleration) and the average MAD was 19.9 ± 6.1 mg. Notably, acceleration summary metrics were higher in men than women and diminished with increasing age. Work generated in the present study will facilitate harmonized analysis, reproducibility, and utilization of NAKO accelerometry data. The NAKO accelerometry dataset represents a valuable asset for physical activity research and will be accessible through a specified application process.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-2322Test

الوصول الحر: https://doaj.org/article/dee20163ca0f46aa9a4e6758800f77eaTest

المؤلفون: Franziska Maria Ippen, Angelika Scherm, Tobias Kessler, Peter Hau, Sarina Agkatsev, Hansjörg Baurecht, Wolfgang Wick, Helge Knüttel, Michael F. Leitzmann, Corinna Seliger‐Behme

المصدر: Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)

مصطلحات موضوعية: glioblastoma, meta‐analysis, progressive, targeted therapies, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background Glioblastoma (GB) is the most common malignant primary brain tumor in adults and is associated with a poor prognosis. Current treatment guidelines outline the standard of care for patients with newly diagnosed GB; however, there is currently no well‐established consensus for the treatment of progressive GB. With this systematic meta‐analysis of recently published randomized controlled trials (RCTs), we aim to establish evidence on targeted agents in the treatment of patients with progressive GB. Material and Methods We conducted searches across the Cochrane Library, Pubmed, MEDLINE (Ovid), ClinicalTrials.gov, WHO‘s International Clinical Trials Registry Platform and Google Scholar, encompassing the time span from 1954 to 2022, aiming to identify RCTs evaluating targeted therapies in patients with progressive GB. In order to perform a random‐effects meta‐analysis, we extracted hazard ratios (HRs) of overall survival (OS) and progression‐free survival (PFS). Results We included 16 RCTs (n = 3025 patients) in the systematic meta‐analysis. Formally, regorafenib (RR 0.50; 95% CI 0.33–0.75), Depatux‐M + TMZ (RR 0.66; 95% CI 0.47–0.93) and rindopepimut + bevacizumab (RR 0.53; 95% CI 0.32–0.88) were associated with an improved OS compared to the control arm. The combination of bevacizumab + CCNU (RR = 0.49; 95% CI 0.35–0.69) and regorafenib (RR 0.65; 95% CI 0.44–0.95) were formally associated with improved PFS. Conclusions The aim of this systematic meta‐analysis was to establish evidence for the use of targeted therapies in progressive GB. While some studies demonstrated benefits for OS and/or PFS, those results have to be interpreted with caution as most studies had major methodological weaknesses, including potential differences in sample size, trial design, or the initial distribution of prognostic factors.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-7634Test

الوصول الحر: https://doaj.org/article/007ab5d0000c42e8bd4284bd7935d960Test

المؤلفون: Michael J. Stein, Hansjörg Baurecht, Anja M. Sedlmeier, Julian Konzok, Patricia Bohmann, Emma Fontvieille, Laia Peruchet-Noray, Jack Bowden, Christine M. Friedenreich, Béatrice Fervers, Pietro Ferrari, Marc J. Gunter, Heinz Freisling, Michael F. Leitzmann, Vivian Viallon, Andrea Weber

المصدر: International Journal of Behavioral Nutrition and Physical Activity, Vol 20, Iss 1, Pp 1-9 (2023)

مصطلحات موضوعية: Physical activity patterns, All-cause mortality, UK Biobank, Raw accelerometry, Nutritional diseases. Deficiency diseases, RC620-627, Public aspects of medicine, RA1-1270

الوصف: Abstract Background The benefit of physical activity (PA) for increasing longevity is well-established, however, the impact of diurnal timing of PA on mortality remains poorly understood. We aimed to derive circadian PA patterns and investigate their associations with all-cause mortality. Methods We used 24 h PA time series from 96,351 UK Biobank participants aged between 42 and 79 years at accelerometry in 2013–2015. Functional principal component analysis (fPCA) was applied to obtain circadian PA patterns. Using multivariable Cox proportional hazard models, we related the loading scores of these fPCs to estimate risk of mortality. Results During 6.9 years of follow-up, 2,850 deaths occurred. Four distinct fPCs accounted for 96% of the variation of the accelerometry data. Using a loading score of zero (i.e., average overall PA during the day) as the reference, a fPC1 score of + 2 (high overall PA) was inversely associated with mortality (Hazard ratio, HR = 0.91; 95% CI: 0.84–0.99), whereas a score of -2 (low overall PA) was associated with higher mortality (1.69; 95% CI: 1.57–1.81; p for non-linearity

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1479-5868Test

الوصول الحر: https://doaj.org/article/a7efca6f0f0449ae9110da037d34a777Test

المؤلفون: Tareq M. Haedenkamp, Michael F. Leitzmann, Ralf A. Linker, Christoph Meier, Claudia Becker, Susan Jick, Peter Hau, Corinna Seliger

المصدر: Cancer Medicine, Vol 12, Iss 3, Pp 3684-3695 (2023)

مصطلحات موضوعية: antibiotics, antifungals, case–control study, glioma, infectious disease, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background The use of antibiotics has been associated with increased risks of various cancers. Comprehensive information on the association of antibiotic use with the risk of glioma is lacking. Methods We performed a large case–control study based on the Clinical Practice Research Datalink (CPRD) GOLD from the United Kingdom. We identified 4423 glioma cases recorded between 1995 and 2020 and matched them to controls (1:10) on the date of diagnosis (i.e., the index date), age, sex, general practice, and number of years of medical history in the database prior to the index date. We conducted conditional logistic regression analyses to calculate odds ratios (ORs) with 95% confidence intervals (CIs). The exposures of interest were the use of antimicrobial drugs, including antibacterial, antiviral, antifungal, antiprotozoal, and anthelmintic drugs with specific subclasses, where possible. Results We found no substantially increased risk of glioma after ever‐use of antibiotics (OR 1.13, 95% CI 1.03–1.24). The risk did not increase with the increasing number of prescriptions received or with increasing time from first use to cancer diagnosis. The use of polyenes was associated with a weakly decreased risk of glioma (OR 0.81, 95% CI 0.67–0.96).

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-7634Test

الوصول الحر: https://doaj.org/article/b47548f6118b41a5b774ca8981649799Test

المؤلفون: Bernadette Ellwanger, Susanne Schüler‐Toprak, Carmen Jochem, Michael F. Leitzmann, Hansjörg Baurecht

المصدر: Cancer Reports, Vol 5, Iss 11, Pp n/a-n/a (2022)

مصطلحات موضوعية: cancer epidemiology, meta‐analysis, obesity, ovarian neoplasm, overweight, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Background Excess weight is convincingly associated with several cancers, but the association with ovarian cancer is insufficiently clarified, in particular regarding subgroups defined by menopausal status and ovarian cancer histologic type. Aims We carried out a comprehensive systematic review and meta‐analysis of overweight and obesity in relation to ovarian cancer with focus on different subgroups. Methods and Results We searched PubMed and Web of Science for relevant cohort and case–control studies published from inception to June 2021 in English language and using a clear definition of overweight and obesity. We combined maximally adjusted risk estimates using a random effects model. We analyzed data from 15 cohort and 26 case–control studies, including 28 471 ovarian cancer cases. The relative risk of ovarian cancer for overweight and obesity was 1.06 (95% confidence interval [CI] = 1.00–1.12) and 1.19 (95% CI = 1.11–1.28), respectively. Among premenopausal women, increased ovarian cancer risk was noted for overweight (RR 1.34; 95% CI = 1.03–1.75) and obesity (RR 1.51; 95% CI = 1.21–1.88). By comparison, among postmenopausal women no statistically significant association was found for overweight (RR 1.00; 95% CI 0.87–1.14) and obesity (RR1.03; 95% CI = 0.82–1.31). Increased risk was found for mucinous (RR 1.44; 95% CI = 1.03–2.01) and clear cell (RR 1.82; 95% CI = 1.11–2.99) ovarian cancer subtypes, but not for serous (RR1.12; 95% CI = 0.84–1.50;) and endometroid subtypes (RR1.24; 95% CI =0.96–1.60). Conclusions Obesity is associated with increased ovarian cancer risk. That relation is largely due to a positive association between adiposity and ovarian cancer among premenopausal but not postmenopausal women and among cases with mucinous and clear cell but not serous or endometrioid histology.

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2573-8348Test

الوصول الحر: https://doaj.org/article/31ec4ae5e7c14ec8b0e216dcca32759eTest

المؤلفون: Eline H. van Roekel, Martijn J. L. Bours, Linda van Delden, Stéphanie O. Breukink, Michèl Aquarius, Eric T. P. Keulen, Audrey Gicquiau, Vivian Viallon, Sabina Rinaldi, Paolo Vineis, Ilja C. W. Arts, Marc J. Gunter, Michael F. Leitzmann, Augustin Scalbert, Matty P. Weijenberg

المصدر: Scientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)

مصطلحات موضوعية: Medicine, Science

الوصف: Abstract We investigated longitudinal associations of moderate-to-vigorous physical activity (MVPA) and light-intensity physical activity (LPA) with plasma concentrations of 138 metabolites after colorectal cancer (CRC) treatment. Self-reported physical activity data and blood samples were obtained at 6 weeks, and 6, 12 and 24 months post-treatment in stage I-III CRC survivors (n = 252). Metabolite concentrations were measured by tandem mass spectrometry (BIOCRATES AbsoluteIDQp180 kit). Linear mixed models were used to evaluate confounder-adjusted longitudinal associations. Inter-individual (between-participant differences) and intra-individual associations (within-participant changes over time) were assessed as percentage difference in metabolite concentration per 5 h/week of MVPA or LPA. At 6 weeks post-treatment, participants reported a median of 6.5 h/week of MVPA (interquartile range:2.3,13.5) and 7.5 h/week of LPA (2.0,15.8). Inter-individual associations were observed with more MVPA being related (FDR-adjusted q-value

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-2322Test

الوصول الحر: https://doaj.org/article/65f1b265c8214ed484172de96993f415Test

المؤلفون: Hansjörg Baurecht, Michael Heinrich, Peter M. Kreuzer, Berthold Langguth, Luisa Hofmann, Michael F. Leitzmann, Corinna Seliger

المصدر: Clinical and Translational Medicine, Vol 12, Iss 6, Pp n/a-n/a (2022)

مصطلحات موضوعية: Medicine (General), R5-920

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2001-1326Test

الوصول الحر: https://doaj.org/article/ef37924b46c64296be01e142c56dbe92Test

المؤلفون: Erik A. Willis, Wen-Yi Huang, Pedro F. Saint-Maurice, Michael F. Leitzmann, Elizabeth A. Salerno, Charles E. Matthews, Sonja I. Berndt

المصدر: BMC Medicine, Vol 18, Iss 1, Pp 1-13 (2020)

مصطلحات موضوعية: Obesity, Weight loss, Mortality, Prospective cohort, Medicine

الوصف: Abstract Background Due to the high prevalence of obesity and the difficulty in maintaining weight loss, repeated bouts of weight loss are a common occurrence. However, there are inconsistencies in epidemiological studies regarding repetitive weight fluctuations being associated with increased risk of mortality. Therefore, the purpose of this prospective cohort analysis was to determine the long-term association of the frequency of weight loss attempts on mortality. Methods This prospective cohort study used data collected from adult AARP members living in 6 states (California, Florida, Louisiana, New Jersey, North Carolina, or Pennsylvania) or 2 metropolitan areas (Atlanta, Georgia, or Detroit, Michigan) and participating in the National Institutes of Health–AARP Diet and Health Study between 2004 and 2006. Self-reported data were analyzed for 161,738 middle-aged adults. During an average 7 years of follow-up, 21,194 deaths were recorded. Hazard ratios of all-cause, cardiovascular, and cancer mortality were estimated adjusting for demographic, lifestyle, and behavioral risk factors. Results Increased frequency of weight loss attempts of at least five pounds was associated with lower mortality (p trend

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12916-020-01716-5Test; https://doaj.org/toc/1741-7015Test

الوصول الحر: https://doaj.org/article/78d8ff1821fa4f8ab11c6f49e674b75bTest

المؤلفون: Tareq M. Haedenkamp, Michael F. Leitzmann, Ralf A. Linker, Christoph Meier, Claudia Becker, Susan Jick, Katharina Sahm, Michael Platten, Peter Hau, Corinna Seliger

المصدر: Cancer Medicine, Vol 9, Iss 3, Pp 1263-1275 (2020)

مصطلحات موضوعية: autoimmune diseases, glioma, immunosuppressive therapies, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

الوصف: Abstract Effectors from the immune system can modulate the course and possibly the early development of gliomas. We, therefore, hypothesized that autoimmune diseases associated with increased immune‐surveillance may also modulate the risk of human glioma. To test this hypothesis, we used data from the well‐validated Clinical Practice Research Datalink (CPRD) GOLD from the UK to analyze the association of immune‐related disorders or use of immunosuppressive drugs and the risk of glioma. We identified 3112 incident glioma cases diagnosed between 1995 and 2017. We randomly selected up to 10 controls, matching them to glioma cases on age, sex, index date, general practice, and number of years of active history in the database prior to the index date. We performed conditional logistic regression analyses to estimate Odds Ratios (ORs) of glioma among those exposed to allergies, autoimmune diseases, and immunosuppressive drugs. Overall, we found no materially altered association between a history of any autoimmune disease (OR 0.98, 95% CI 0.86‐1.11), allergy (OR 0.97, 95% CI 0.89‐1.05), or use of immunosuppressive drugs and the risk of glioma. However, subgroup analyses among younger patients found a statistically significant increased risk of glioma in patients with a history of inflammatory bowel disease (IBD) (OR 2.59, 95% CI 1.31‐5.12). There was also an inverse association between asthma and risk of glioma in patients with longer survival (OR 0.73, 95% CI 0.58‐0.91) and between long‐term duration diabetes and risk of glioma (OR 0.71, 95% CI 0.53‐0.96).

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2045-7634Test

الوصول الحر: https://doaj.org/article/f19ed228d7bf43808c7829f53fa14f5dTest

المؤلفون: Charles E. Matthews, David Berrigan, Beate Fischer, Sjaan R. Gomersall, Andrea Hillreiner, Youngwon Kim, Michael F. Leitzmann, Pedro Saint-Maurice, Timothy S. Olds, Gregory J. Welk

المصدر: BMC Public Health, Vol 19, Iss S2, Pp 1-13 (2019)

مصطلحات موضوعية: Energy expenditure, Sitting time, Behaviour change, Measurement, Exposure assessment, Ecological momentary assessment, Public aspects of medicine, RA1-1270

الوصف: Abstract Background The last few years have seen renewed interest in use-of-time recalls in epidemiological studies, driven by a focus on the 24-h day [including sleep, sitting, and light physical activity (LPA)] rather than just moderate-vigorous physical activity (MVPA). This paper describes four different computerised use-of-time instruments (ACT24, PAR, MARCA and cpar24) and presents population time-use data from a collective sample of 8286 adults from different population studies conducted in Australia/New Zealand, Germany and the United States. Methods The instruments were developed independently but showed a number of similarities: they were self-administered through the web or used computer-assisted telephone interviews; all captured energy expenditure using variants of the Ainsworth Compendium; each had been validated against criterion measures; and they used a domain structure whereby activities were aggregated under categories such as Personal Care and Work. Results Estimates of physical activity level (average daily rate of energy expenditure in METs) ranged from 1.53 to 1.78 in the four studies, strikingly similar to population estimates derived from doubly labelled water. There was broad agreement in the amount of time spent in sleep (7.2–8.6 h), MVPA (1.6–3.1 h), personal care (1.6–2.4 h), and transportation (1.1–1.8 h). There were consistent sex differences, with women spending 28–81% more time on chores, 8–40% more time in LPA, and 3–39% less time in MVPA than men. Conclusions Although there were many similarities between instruments, differences in operationalizing definitions of sedentary behaviour and LPA resulted in substantive differences in the amounts of time reported in sedentary and physically active behaviours. Future research should focus on deriving a core set of basic activities and associated energy expenditure estimates, an agreed classificatory hierarchy for the major behavioural and activity domains, and systems to capture relevant social and environmental contexts.

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12889-019-6763-8Test; https://doaj.org/toc/1471-2458Test

الوصول الحر: https://doaj.org/article/b2f4860e78d7491689e6fcbfe4e444a4Test